Alan Kwong established PharmEng Technology in 1997 and is currently the CEO and Chairman with over 120 staff in Asia, USA and Canada.
Mr. Kwong has been in the pharmaceutical, biotechnology and medical devices industries for over 20 years and has leveraged that experience into the global expansion of consulting operations, serving 7 of the top 10 pharmaceutical companies in the world.
Mr. Kwong continues to drive PharmEng Technology, a premier consulting firm, leading consultants to provide high-level of expertise to all clients.
Ben Lee brings over 25 years experience in all aspects of Project Management. He has successfully delivered over $1B in major projects in the biotechnology, pharmaceutical, hospital and manufacturing sectors from concept to completion.
Mr. Lee has comprehensive knowledge and practice of current GMP, GLP, FDA and CFR 21 Part 11. He possesses direct and extensive experience in project planning such as benefit-cost analysis, life cycle costing, feasibility studies, change control, operational/technical requirements, analysis & optimization, functional/space programming, land use and environmental approvals.
Mr. Lee has been invited to speak at several associations, including the ISPE conference as a keynote speaker.
Kenny Peng P.Eng, M.A.Sc., R.A.C.
Kenny Peng is based in Singapore and Taiwan and possesses 10 years of experience as a Project Manager and Business Manager.
Mr. Peng is a consulting professional whose experiences have spanned start-up, technology transfer, commissioning, validation, audits, regulatory affairs, and engineering, having worked with clients in pharmaceutical, biotechnology, medical device, and food industries across North America and East Asia, including multinational and domestic clients.
Mr. Peng has published articles in Pharmaceutical Engineering Magazine.
Alex Della Mora has 20 years experience in various areas of drug development including cGMP Manufacturing, Quality Systems, Compliance, Audits (cGMP), Validation, Clinical Operations and Quality Assurance.
Mr. Della Mora has successfully lead the management of projects in a fast paced environment, with limited resources and implemented various procedures/systems. His excellent communication and customer service skills have resulted in successful project completion and soaring client satisfaction.
David Mayers brings over 25 years of pharmaceutical leadership, with extensive experience in corporate strategy, Quality, Lean Manufacturing, Supply Chain, product launch and product transfer, general management, R&D, capital procurement and implementation and facility expansion.
Prior to joining PharmEng, Mr. Mayers was formerly President of WellSpring Pharma Services, and VP of Manufacturing Operations at Purdue Pharma
Nizamil Fairuz Yahya has a diverse global experience in R&D, Medical devices and Pharmaceutical industries..
Mr. Fairuz has demonstrated excellent compliance solutions in GxP enforcement. His current advisory roles focus on quality system, commissioning, qualification and validation, compliance remedication, GxP training and quality behavior coaching. Mr. Fairuz's professional career traverses from consulting to project management experience within Americas and Asia Pacific region, serving multinational and domestic clients focused on GMP.
Yeeju Chen, as a registered pharmacist in Singapore, brings with her a diverse and valuable knowledge of the Asian pharmaceutical market.
Ms. Chen's insight into the pharmaceutical industry encompasses quality assurance and regulatory compliance, spanning from drug discovery to biomedical development, manufacturing and to market access. She has led undergraduate, postgraduate and professional training programs at the National University of Singapore's Department of Pharmacy. Ms. Chen also brings extensive networks and commerical management expertise in product and inventory management, merchandising, branding, sales and marketing of FMCG and pharmaceutical products on both B2B and B2C platforms, contributing to successful operational execution of businesses. She now leads the Regulatory Affairs team in South East Asia, overseeing various product registration projects across different product classifications, ranging from Biologics/Biosimilars to Pharmaceuticals to Medical Devices etc.
Alice Wang provides financial management services and leads office administrative functions for over 10 years. Her responsibilities include financial planning, monitoring, reporting, risk control and internal control.
Ms. Wang has an eye for continuous improvement. She also provides both operational and programmatic support to the organization and assists operation managers on budget management, cost benefit analysis, forecasting needs and efficiency improvements.
Jake Thiessen is a former Professor, Associate Dean, and current Professor Emeritus at the Leslie Dan Faculty of Pharmacy, University of Toronto. Following 33 years at the University of Toronto, he spent 6 years at the University of Waterloo (UW) where he had strategic responsibility for the development of a new Health Sciences Campus and Canada's 10th School of Pharmacy.
Jack Thiessen specialized in pharmacokinetics and pharmacodynamics, which basically describe quantitatively those forces that affect how the body handles medicines and how medicines affect the body. The dynamic of these two areas influences strategies around patient treatment regimen in all disease states. Research collaborations included some years working with medical oncologists and basic scientists at Princess Margaret Hospital.
Mr. Thiessen's broad experience has included international projects in areas like Taiwan, Saudi Arabia, Sudan and Nigeria, the role of CCAPP President, Chair for the Drug Quality and Therapeutics Committee of the Ontario Ministry of Health, and Chair for Health Canada's Scientific Advisory Committee on Bioavailability and Bioequivalence. Currently he serves Health Canada as the Chair of the Scientific Advisory Committee on Pharmaceutical Sciences and Clinical Pharmacology. Most recently, he served the Ontario Minister of Health and Long Term Care as an independent reviewer of the under-dosing of oncology medicines discovered in Ontario. In recognition of his lifelong service as educator, researcher, mentor, innovator and leader he was honoured with the 2014 Canadian Pillar of Pharmacy Award.
Mr. Joshi holds extensive expertise in pharmaceutical solid dosage formulation and process development and is an expert in conceptual design for sterile and non-sterile manufacturing, filling and packaging operations in pharmaceutical and biotechnology sectors. He is an innoviative strategist, skilled at assessing and implementing cost effective solutions with efficient training.
Mr. Joshi's business acumen and unique perspective have provided effective solutions to all clients.
Hank Klakurka has over 40 years in the pharmaceutical industry and has extensive experience in both branded and generic pharmaceuticals. He played a key role in the sale of Merck's generics division, at the end of 2007, to Pittsburgh-based Mylan Labs for US$6.7B, representing a near-record multiple for the sector. He grew the Merck Generics business from approximately €900M to €1.8B since joining the company in 2001 as head of its Americas Region. He was promoted to CEO of the global group in 2003. The Merck Generics Group was the third largest global generics pharmaceutical company doing business in over 90 countries with a staff of 5000+ employees located in more than 35 countries around the world.
Prior to joining Merck, Mr. Klakurka held progressively more resposible positions with several other major pharmaceutical companies including Astra, Schering-Plough, Johnson & Johnson and Apotex.
Some of Mr. Klakurk's former roles include:
Former CEO, Merck Generics Group, Division of Merck KGaA, Germany
Director, Soho Global Health, Indonesia
Director, Blue-Zone Technologies Ltd., Toronto, Canada
Operating Partner, Quadria Capital Investment Management, Singapore, India
Pharma and Non-Pharma Advisor, several private equity firms, USA, EU, SEA
Pharma Industry Consultant
Bob Hill is a business leader and a Chartered Accountant with 30 years of experience in the pharmaceutical, biotechnology, consumer packaged goods and retail areas.
Mr. Hill has a long track record of driving exceptional top and bottom line growth acting as a strategic partner to the CEO. His strong business acumen gained through a diversity of experiences including time as a sales executive, combined with his leadership skills creates a winning formula.
Mr. Hill has been successful working in both small and large companies, private equity and multi-national companies. He is formerly Chief Financial Officer of Motion Specialities and was previously VP Finance at Biogen Idec and VP Finance at Sanofi Pasteur. He has also worked in senior positions for GSK, Nestle and Campbell Soup and started his career with Price Waterhouse.
The Honourable Philip Lee was named Manitoba's first Chinese-Canadian lieutenant-governor by Prime Minister Stephen Harper in 2009.
Born in Hong Kong, Mr. Lee came to Canada to study chemistry at the University of Manitoba. During his student career, he was elected Chairman of the University College Student Association. In June, 2011 he was awarded an Honorary Doctor of Laws Degree by the University of Manitoba. Mr. Lee began his career as a research chemist, where he worked in the area of water research, dealing with water supply and water quality studies for the City of Winnipeg. While building a career in chemistry and business, Philip continued his community work and was active in Winnipeg's Chinese-Canadian community for over 35 years.
Philip was appointed a member of the Human Rights Council of Manitoba and later became chairperson of the policy review committee for Human Rights, Manitoba. He served as a member of the City of Winnipeg's Refugee Assistance Committee. In addition to being an Executive Board Member of the Winnipeg Chinese Cultural and Community Centre, he was also a member of the Chinese Development Corporation and the 1995 Manitoba's 125th Anniversary Committee.
Philip was inducted into the Order of Canada in 1999. He was the recipient of The Queen's Golden Jubilee Medal in 2002 and The Queen's Diamond Jubiee Medal in 2012. He became a member and the Chancellor of the Order of Manitoba in August 2009.
Philip's leadership has also been recognized through the City of Winnipeg Community Service Award(1984). He served on the Multiculturalism Council of Canada between 1984 and 1988 and received the Recognition of Service Award from the Community and Race Relations Committee, City of Winnipeg(1990). in 1993, Philip received the Commemorative Medal for the 125th Anniversary of Canadian Confederation. Between 1995 and 1999, Mr. Lee was a board member of the Winnipeg Symphony Orchestra and a board member of the Alumi Association of the University of Manitoba.